Home News FDA Panel: All Thumbs Down for Antibody to Treat Metastatic Neuroblastoma back to News
minute read
An FDA advisory committee voted unanimously against recommending approval of the radiolabeled monoclonal antibody I-omburtamab for progressive neuroblastoma with central nervous system/leptomeningeal metastases.
Topics: Press Coverage
1665 North Aurora Court
2004
Aurora, CO 80045
720-848-0300
© 2024 The Regents of the University of Colorado, a body corporate. All rights reserved.
Accredited by the Higher Learning Commission. All trademarks are registered property of the University. Used by permission only.
